SeptRx Completes Enrollment for its “InterSEPT” CE Mark Trial

SeptRx reported today that it has completed enrollment for its “InterSEPT” (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.
MarketWatch